FS Development Corp. II (FSII) Short Interest Ratio & Short Volume

Short interest is the volume of FS Development Corp. II shares that have been sold short but have not yet been closed out or covered. As of November 30th, traders have sold 39,800 shares of FSII short. 0.20% of FS Development Corp. II's shares are currently sold short. Learn More on FS Development Corp. II's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.20% of FS Development Corp. II's floating shares are currently sold short.

FS Development Corp. II saw a increase in short interest during the month of November. As of November 30th, there was short interest totaling 39,800 shares, an increase of 0.8% from the previous total of 39,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

FS Development Corp. II currently has issued a total of 20,727,000 shares. Some of FS Development Corp. II's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. FS Development Corp. II currently has a public float of 20,050,000 shares.

0.20% of FS Development Corp. II's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to FS Development Corp. II: Trevi Therapeutics, Inc. (1.28%), Lifecore Biomedical, Inc. (6.30%), Acrivon Therapeutics, Inc. (4.98%), Galectin Therapeutics Inc. (6.47%), Rigel Pharmaceuticals, Inc. (2.95%), Omeros Co. (23.62%), Generation Bio Co. (3.26%), Ovid Therapeutics Inc. (4.78%), Atossa Therapeutics, Inc. (9.86%), Renovaro Inc. (2.16%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Advanced Micro Devices, Inc. ($11.35 billion), S&P Global Inc. ($8.85 billion), Charter Communications, Inc. ($5.23 billion), Canadian Pacific Kansas City Limited ($4.96 billion), Wayfair Inc. ($3.99 billion), Palo Alto Networks, Inc. ($3.89 billion), Etsy, Inc. ($2.57 billion), Zscaler, Inc. ($2.44 billion), eBay Inc. ($2.34 billion), and Teladoc Health, Inc. ($2.30 billion). View all of the most shorted stocks.

Short selling FSII is an investing strategy that aims to generate trading profit from FS Development Corp. II as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for FS Development Corp. II occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FSII, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FSII, twice per month. The most recent reporting period available is November, 30 2021.